Androgenetic Alopecia - Pipeline Insight, 2026
Description
DelveInsight’s, “Androgenetic Alopecia - Pipeline Insight, 2026” report provides comprehensive insights about 48+ companies and 52+ pipeline drugs in Androgenetic Alopecia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Androgenetic Alopecia: Overview
Androgenetic alopecia, commonly referred to as male or female pattern baldness, is the most prevalent form of hair loss and is driven by genetic susceptibility and androgen hormones, particularly dihydrotestosterone (DHT). The condition follows characteristic patterns, with frontal hairline recession and crown thinning in men, and diffuse thinning over the central scalp in women. DHT shortens the anagen (growth) phase of the hair cycle, leading to progressive follicular miniaturization. Additional factors such as inflammation, perifollicular fibrosis, and altered follicular metabolism further contribute to disease progression.
Clinically, androgenetic alopecia presents as gradual hair thinning with replacement of thick terminal hairs by finer vellus hairs and increased hair shedding. In men, it typically manifests as bitemporal recession and vertex thinning, while women experience diffuse central thinning with preservation of the frontal hairline. The scalp remains non-scarring with visible follicular openings but reduced hair density. Symptoms are usually asymptomatic, though some individuals may report mild itching or scalp sensitivity.
Diagnosis of Androgenetic alopecia is primarily clinical, based on characteristic patterns of gradual hair thinning along with a relevant family history. In men, it typically presents as frontal hairline recession and vertex thinning, while women show diffuse central scalp thinning with preservation of the frontal hairline. Trichoscopy is commonly used to support diagnosis by revealing variation in hair shaft diameter and miniaturized follicles without signs of scarring. Additional investigations, such as scalp biopsy or laboratory testing, are reserved for atypical presentations or when alternative diagnoses need to be excluded.
Management focuses on slowing disease progression and promoting hair regrowth through a combination of medical and procedural approaches. First-line therapies include topical minoxidil and oral finasteride, often used together for enhanced efficacy. Procedural options such as hair transplantation, platelet-rich plasma therapy, and low-level laser therapy can further improve follicular survival and hair density. Emerging regenerative strategies, including growth factor concentrates and stem cell–based therapies, are under investigation, with optimal outcomes typically achieved through sustained, multimodal treatment approaches.
""Androgenetic Alopecia- Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Androgenetic Alopecia pipeline landscape is provided which includes the disease overview and Androgenetic Alopecia treatment guidelines. The assessment part of the report embraces, in depth Androgenetic Alopecia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Androgenetic Alopecia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Androgenetic Alopecia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Androgenetic Alopecia Emerging Drugs
VDPHL01: Veradermics
VDPHL01 is an investigational, orally administered extended-release minoxidil tablet currently in Phase III development for the treatment of pattern hair loss in both men and women. It is a non-hormonal therapy designed using proprietary extended-release technology to enhance both efficacy and safety. The formulation incorporates a gel matrix system that enables a controlled, sustained release of minoxidil, promoting consistent systemic exposure. This approach helps minimize peak drug concentrations seen with immediate-release formulations while maintaining drug levels above the threshold required for hair growth. If approved, VDPHL01 could become the first FDA-approved oral non-hormonal therapy for pattern hair loss, supported by a strong patent portfolio extending to at least 2043.
PP405: Pelage Pharmaceuticals
PP405 is a novel, non-invasive topical small molecule therapy developed to stimulate hair regrowth by reactivating dormant hair follicle stem cells. It targets key metabolic pathways that control the activation cycles of these stem cells, thereby promoting the transition to active hair growth. Early Phase I clinical data demonstrated that PP405 was well tolerated and achieved statistically significant activation of hair follicle stem cells. The intellectual property for PP405 and related compounds was licensed by Pelage Pharmaceuticals from University of California, Los Angeles in 2018. The therapy is currently being evaluated in Phase II clinical trials for the treatment of Androgenetic Alopecia.
ABS-201: Absci Corp
ABS-201 is an investigational therapeutic being developed for the treatment of Androgenetic Alopecia. It is designed to promote hair regrowth by targeting underlying biological mechanisms involved in follicle miniaturization and hair cycle disruption. The therapy aims to improve hair density and thickness while maintaining a favorable safety profile. ABS-201 is currently under clinical evaluation, reflecting its potential as a novel treatment option for patients with pattern hair loss. Currently, ABS-201 is in Phase I/II stage of its development for Androgenetic Alopecia.
ET-02: Eirion Therapeutics, Inc.
ET-02 is a topical small molecule therapy being developed for the treatment of Androgenetic Alopecia. It utilizes a novel mechanism of action aimed at correcting dysfunction in hair follicle stem cells, which are believed to play a key role in the development of alopecia. By targeting this underlying cause, ET-02 is designed to promote hair regrowth and restore normal follicle function. According to the company’s pipeline the drug is currently in Phase I stage of development.
YR-001: YIRUI Pharmaceutical Technology
YR-001 is an investigational topical therapy being developed for the treatment of Androgenetic Alopecia. It is designed to target potassium channel pathways (Kv1.3), which are implicated in hair follicle function and cycling. By modulating these pathways, YR-001 aims to promote hair regrowth and improve follicle health. The drug is currently under evaluation, highlighting its potential as a novel non-invasive treatment option for pattern hair loss. The drug is in preclinical stage of its development for the treatment of alopecia.
Further product details are provided in the report……..
Androgenetic Alopecia: Therapeutic Assessment
This segment of the report provides insights about the different Androgenetic Alopecia drugs segregated based on following parameters that define the scope of the report, such as:
Androgenetic Alopecia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Androgenetic Alopecia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Androgenetic Alopecia drugs.
Androgenetic Alopecia Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Androgenetic Alopecia: Overview
Androgenetic alopecia, commonly referred to as male or female pattern baldness, is the most prevalent form of hair loss and is driven by genetic susceptibility and androgen hormones, particularly dihydrotestosterone (DHT). The condition follows characteristic patterns, with frontal hairline recession and crown thinning in men, and diffuse thinning over the central scalp in women. DHT shortens the anagen (growth) phase of the hair cycle, leading to progressive follicular miniaturization. Additional factors such as inflammation, perifollicular fibrosis, and altered follicular metabolism further contribute to disease progression.
Clinically, androgenetic alopecia presents as gradual hair thinning with replacement of thick terminal hairs by finer vellus hairs and increased hair shedding. In men, it typically manifests as bitemporal recession and vertex thinning, while women experience diffuse central thinning with preservation of the frontal hairline. The scalp remains non-scarring with visible follicular openings but reduced hair density. Symptoms are usually asymptomatic, though some individuals may report mild itching or scalp sensitivity.
Diagnosis of Androgenetic alopecia is primarily clinical, based on characteristic patterns of gradual hair thinning along with a relevant family history. In men, it typically presents as frontal hairline recession and vertex thinning, while women show diffuse central scalp thinning with preservation of the frontal hairline. Trichoscopy is commonly used to support diagnosis by revealing variation in hair shaft diameter and miniaturized follicles without signs of scarring. Additional investigations, such as scalp biopsy or laboratory testing, are reserved for atypical presentations or when alternative diagnoses need to be excluded.
Management focuses on slowing disease progression and promoting hair regrowth through a combination of medical and procedural approaches. First-line therapies include topical minoxidil and oral finasteride, often used together for enhanced efficacy. Procedural options such as hair transplantation, platelet-rich plasma therapy, and low-level laser therapy can further improve follicular survival and hair density. Emerging regenerative strategies, including growth factor concentrates and stem cell–based therapies, are under investigation, with optimal outcomes typically achieved through sustained, multimodal treatment approaches.
""Androgenetic Alopecia- Pipeline Insight, 2026"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Androgenetic Alopecia pipeline landscape is provided which includes the disease overview and Androgenetic Alopecia treatment guidelines. The assessment part of the report embraces, in depth Androgenetic Alopecia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Androgenetic Alopecia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Androgenetic Alopecia R&D. The therapies under development are focused on novel approaches to treat/improve Androgenetic Alopecia.
This segment of the Androgenetic Alopecia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Androgenetic Alopecia Emerging Drugs
VDPHL01: Veradermics
VDPHL01 is an investigational, orally administered extended-release minoxidil tablet currently in Phase III development for the treatment of pattern hair loss in both men and women. It is a non-hormonal therapy designed using proprietary extended-release technology to enhance both efficacy and safety. The formulation incorporates a gel matrix system that enables a controlled, sustained release of minoxidil, promoting consistent systemic exposure. This approach helps minimize peak drug concentrations seen with immediate-release formulations while maintaining drug levels above the threshold required for hair growth. If approved, VDPHL01 could become the first FDA-approved oral non-hormonal therapy for pattern hair loss, supported by a strong patent portfolio extending to at least 2043.
PP405: Pelage Pharmaceuticals
PP405 is a novel, non-invasive topical small molecule therapy developed to stimulate hair regrowth by reactivating dormant hair follicle stem cells. It targets key metabolic pathways that control the activation cycles of these stem cells, thereby promoting the transition to active hair growth. Early Phase I clinical data demonstrated that PP405 was well tolerated and achieved statistically significant activation of hair follicle stem cells. The intellectual property for PP405 and related compounds was licensed by Pelage Pharmaceuticals from University of California, Los Angeles in 2018. The therapy is currently being evaluated in Phase II clinical trials for the treatment of Androgenetic Alopecia.
ABS-201: Absci Corp
ABS-201 is an investigational therapeutic being developed for the treatment of Androgenetic Alopecia. It is designed to promote hair regrowth by targeting underlying biological mechanisms involved in follicle miniaturization and hair cycle disruption. The therapy aims to improve hair density and thickness while maintaining a favorable safety profile. ABS-201 is currently under clinical evaluation, reflecting its potential as a novel treatment option for patients with pattern hair loss. Currently, ABS-201 is in Phase I/II stage of its development for Androgenetic Alopecia.
ET-02: Eirion Therapeutics, Inc.
ET-02 is a topical small molecule therapy being developed for the treatment of Androgenetic Alopecia. It utilizes a novel mechanism of action aimed at correcting dysfunction in hair follicle stem cells, which are believed to play a key role in the development of alopecia. By targeting this underlying cause, ET-02 is designed to promote hair regrowth and restore normal follicle function. According to the company’s pipeline the drug is currently in Phase I stage of development.
YR-001: YIRUI Pharmaceutical Technology
YR-001 is an investigational topical therapy being developed for the treatment of Androgenetic Alopecia. It is designed to target potassium channel pathways (Kv1.3), which are implicated in hair follicle function and cycling. By modulating these pathways, YR-001 aims to promote hair regrowth and improve follicle health. The drug is currently under evaluation, highlighting its potential as a novel non-invasive treatment option for pattern hair loss. The drug is in preclinical stage of its development for the treatment of alopecia.
Further product details are provided in the report……..
Androgenetic Alopecia: Therapeutic Assessment
This segment of the report provides insights about the different Androgenetic Alopecia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Androgenetic Alopecia
- There are approx. 48+ key companies which are developing the therapies for Androgenetic Alopecia. The companies which have their Androgenetic Alopecia drug candidates in the most advanced stage, i.e. Phase III include, Veradermics.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Androgenetic Alopecia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Androgenetic Alopecia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Androgenetic Alopecia drugs.
Androgenetic Alopecia Report Insights
- Androgenetic Alopecia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Androgenetic Alopecia drugs?
- How many Androgenetic Alopecia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Androgenetic Alopecia?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Androgenetic Alopecia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Androgenetic Alopecia and their status?
- What are the key designations that have been granted to the emerging drugs?
- Veradermics
- Pelage Pharmaceuticals
- Suzhou Kintor Pharmaceuticals
- Dermaliq
- Absci Corp
- YIRUI Pharmaceutical Technology
- Amplifica
- Eirion Therapeutics, Inc.
- BioResearch Pharma S.A.
- AnHorn Medicines Co. Ltd.,
- Triple Hair Group Inc
- Moogene Medi Co., Ltd
- OliX Pharmaceuticals
- Xtressé
- Hope Medicine
- VDPHL01
- PP405
- GT20029
- DLQ01
- ABS-201
- YR 001
- AMP 601
- ET-02
- BRP-011
- AH-001
- TH07
- AD-303A
- OLX72021
- Xvie
- HMI-115
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Androgenetic Alopecia: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Androgenetic Alopecia– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- VDPHL01: Veradermics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- PP405: Pelage Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ET 02: Eirion Therapeutics, Inc.
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Inactive Products
- Comparative Analysis
- Androgenetic Alopecia Key Companies
- Androgenetic Alopecia Key Products
- Androgenetic Alopecia- Unmet Needs
- Androgenetic Alopecia- Market Drivers and Barriers
- Androgenetic Alopecia- Future Perspectives and Conclusion
- Androgenetic Alopecia Analyst Views
- Androgenetic Alopecia Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
